Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts
CCO
0.003
50%
NAE
0.001
-50%
M2R
0.003
50%
AOK
0.002
-33.3%
TOU
0.003
50%
MQR
0.006
-25%
AVE
0.021
40%
KM1
0.081
-22.9%
BLU
0.004
33.3%
COI
0.102
-21.5%
HIQ
0.008
33.3%
KTA
0.004
-20%
BNZ
2.67
25.9%
XGL
0.008
-20%
M2M
0.01
25%
VIT
0.021
-19.2%
TGH
0.02
25%
CYP
0.013
-18.8%
UM1
0.145
20.8%
BTE
0.04
-18.4%
AGD
0.12
20%
LIS
0.115
-17.9%
AZI
0.024
20%
5GG
0.014
-17.6%
OEL
0.006
20%
AVD
0.1
-16.7%
SIX
0.083
18.6%
ENL
0.005
-16.7%
LKO
0.6
17.6%
FEL
0.005
-16.7%
NH3
0.11
17%
RBX
0.03
-16.7%
PL9
0.007
16.7%
YUG
0.06
-16.7%
SIS
0.007
16.7%
NOR
0.032
-15.8%
CVC
1.7
16.4%
BNL
0.006
-14.3%
MEL
0.016
14.3%
PET
0.006
-14.3%
